

The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed, the Part B NDC Identity Gap, and a 14-Day Event Clock

JUL 26, 2026 • PAID



 **Part I Podcast free on Spotify.**



Thoughts on Healthcare Markets & Technology



Part I: The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed and the Part B NDC Identity Gap

CMS's draft MTF guidance is the most detailed operational document in the entire IRA drug pricing rollout, and almost everyone is going to misread the 14-day clock...

 Listen now

8 minutes ago · Thoughts on Healthcare

 **Part II Podcast episode for paid subscribers only. Also available on Spotify.**



Part II: The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed and the Part B NDC Identity Gap

CMS's draft MTF guidance is the most detailed operational document in the entire IRA drug pricing rollout, and almost everyone is going to misread the 14-day clock...

 Listen now

7 minutes ago · Thoughts on Healthcare

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

- The July 2028-effectuation document is draft guidance, not final policy. Comments closed June 26, 2025. Every design choice below carries a draft label.
- The core idea: a negotiated maximum fair price only becomes real when a claim-level event proves who owes what to whom. Claims and encounters flow into the Medicare Transaction Facilitator, it identifies eligible events and ships claim data to the primary manufacturer, the manufacturer effects or explains the discount, and a standardized status record flows back.
- The MTF is not the payer. It does not owe the discount and does not replace ordinary Medicare claim payment. It's a data layer, plus an optional payment switch.
- Two modules, two legal weights: the Data Module (mandatory reporting) and Payment Module (optional routing). Manufacturers register for the Data Module.

by May 1, 2027 for prices effective January 1, 2028.

- Part D rides a Prescription Drug Event feed, now shortened to seven days for selected drugs, gated by eligibility edits. Part B has a nastier problem: one HCPCS can hold several products, so the claim may not even say which drug was.
- The 14-day clock is a manufacturer event deadline that starts when verified is sent, not a promise the provider gets cash within 14 days of administrative Read that sentence twice.
- Every record gets a status code. Effectuation becomes a computable audit log CMS does not validate whether the refund math is actually right.

Table of Contents

A price is only real once a claim-level event proves who owes what to whom

Draft, not final, and why that word governs everything

Two modules, two very different legal weights

The Part D feed: a seven-day PDE stream behind an eligibility gate

The Part B identity problem: one HCPCS, many products

Three pipelines, three clocks

The 14-day clock is an event deadline, not a receipt

Enrollment, banking, and the ERA are the actual control system

The Payment Module is a switch, not a guarantor

Status codes and credits, or how effectuation becomes an audit log

Thoughts on Healthcare Markets &
Technology is a reader-supported

publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

A price is only real once a claim-level event proves who owes what to whom

The negotiated-price program produces a number, the maximum fair price, but that number is not money, and the entire draft effectuation guidance is CMS working out how that number turns into an actual dollar moving to an actual entity. The mechanism it lands on is a claim-level reconciliation rail. Claims from Part D, and claims or encounters from Part B, flow into a Medicare Transaction Facilitator. The facilitator figures out which of those events are eligible for the negotiated price, packages the claim-level data, and sends it to the drug's primary manufacturer. The manufacturer then either effects the discount, pays a refund, or explains why it cannot, and a standardized status record flows back to CMS for reconciliation and oversight. The price becomes real only at the moment a specific claim-level event establishes who owes what to whom.

The most important thing to get straight before anything else is what the facilitator is not. It is not the payer. It does not itself owe the negotiated discount, and it does not replace the ordinary Medicare claim payment that already happened through the normal benefit. The underlying claim gets paid the usual way, by the usual entity, on the usual terms. The facilitator sits alongside that as a data-and-optional-payment layer, the plumbing through which a manufacturer provides retrospective access to the negotiated price in the common case where that price was not already baked into the acquisition cost up front. Miscasting the facilitator as the payer, or as a replacement for claims adjudication, gets the architecture backward from the first sentence, and a lot of commentary is going to do exactly that.





Continue reading this post for free, courtesy of Thoughts on
Healthcare.

Claim my free post

Or purchase a paid subscription.

← Previous

© 2026 Healthcare Markets & Technology · [Privacy](#) • [Terms](#) • [Collection notice](#)
[Substack](#) is the home for great culture